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Within the Flaviviradae family, the genus Flavivirus contains 
over 70 viruses with a growing number of unclassified members.I 
Many Flavivirus members are known to cause severe disease, such 
as Dengue hemorrhagic fever, sometimes associated to human 
mortality.1-4 Members of this genus, including Dengue virus 
(DENV), West Nile Virus (WNV), Zika Virus (ZIKV), Yellow 
Fever Virus (YFV), and tick-borne encephalitis virus (TBEV), 
represent a tremendous health burden.1-5 Of these lethal 
flaviviruses, DENV poses the most severe threat with over 50 
million documented cases, and between 12,500 and 25,000 deaths 
reported annually.3, 6, 7 Recently it was discovered that ZIKV 
infections in pregnant women have led to numerous infant 
abnormalities including microcephaly and severe brain 
malformations, as well as the development of Guillain-Barré 
syndrome in adults.2, 5, 7-9 Furthermore, more recent studies have 
demonstrated that ZIKV infections are sexually transmittable, with 
a detectable viral load in semen up to 26 weeks post symptomatic 
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onset.10-16 Unfortunately, due to increased globalization, it is 
inevitable that new, undiscovered flaviviruses will continue to 
spread, endangering populations worldwide. As a result, new and 
viable therapeutic options need to be developed in order to better 
combat these emerging infections. 
Flaviviruses are single stranded, positive-sense RNA viruses, 
with capped genomes of approximately 11 kb in length.3, 17, 18 The 
genome contains an untranslated 5’-region followed by a single 
open reading frame and an untranslated 3’-end region.3, 17, 19 The 
open reading frame encodes for three structural proteins (capsid, 
pre-membrane, and envelope), as well as seven non-structural 
(NS) proteins forming the replication transcription complex.  
Among these NS proteins, the NS3 multifunctional protein has 
been shown to harbor serine protease, 5’-RNA triphosphatase 
(RTPase), nucleoside triphosphatase (NTPase), and helicase 
activities. The NS5 protein is another multifunctional protein 
essential for virus replication, which is responsible for the RNA-
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Flaviviruses, such as Dengue (DENV) and Zika (ZIKV) viruses, represent a severe health burden. 
There are currently no FDA-approved treatments, and vaccines against most flaviviruses are still 
lacking. We have developed several flexible analogues (“fleximers”) of the FDA-approved 
nucleoside Acyclovir that exhibit activity against various RNA viruses, demonstrating their broad-
spectrum potential. The current study reports activity against DENV and YFV, particularly for 
compound 1. Studies to elucidate the mechanism of action suggest the flex-analogue 
triphosphates, especially 1-TP, inhibit DENV and ZIKV methyltransferases. The results of these 













dependent-RNA-polymerase (RdRp) and methyl transferase 
(MTase) activities needed for RNA capping (Figure 1).1- 3, 17-20 
 
Of the seven flavivirus MS proteins, one of the most important 
targets for drug design is the NS5 protein, which is the most 
conserved protein of the flaviviruses and plays an essential role in 
viral replication and capping. The C-terminal domain of the NS5 
protein contains the RdRp domain and the N-terminal domain is 
responsible for the S-adenosyl-L-methionine (SAM) dependent 
N7 and 2’-O-MTase activity for the viral RNA.6, 21-23 The 
aforementioned MTase activities modify the cap structure of the 
flaviviral RNA through N7-methylation of the 5’-guanine of the 
cap structure and 2’-O-methylation of the first transcribed 
adenosine nucleotide (N7MEGpppA2’OMe-RNA) (Figure 2). 6, 21-24 
 
The canonical RNA capping pathway of eukaryotic cells 
requires four main enzyme activities: (i) RTPase (NS3 in 
flaviviruses) that hydrolyzes the 5’-triphosphate end of the nascent 
RNA transcript into a 5’-diphosphate;25 (ii) RNA 
guanylyltransferase (putatively NS5) which then transfers the 
GMP moiety of GTP to the 5’-nucleotide diphosphate end;26 (iii) 
the RNA (guanine-N7)-MTase) that methylates the N7 position on 
the 5’-guanine; (iv) RNA (nucleoside-2’-O)-MTase methylates the 
2’-OH (a conserved adenosine in flaviviruses) of the subsequent 
nucleotide, resulting in cap-1 structure for the viral RNA.6, 21, 22, 24, 
27-29 Both methylation reactions are catalyzed by a single MTase 
domain and SAM is used as a methyl donor, generating S-
adenosyl-L-homocysteine (SAH) as a by-product.28, 29  
All flaviviral MTases share a conserved Rossmann-fold 
structure consisting of a SAH/SAM binding site, a cap/GTP 
binding site, and an RNA-binding pocket.28-30 Studies have shown 
that the presence of the methylated 5’ cap is essential for the 
protection and stability of the viral RNA throughout the viral 
replication cycle; thus, disruption of the MTase activity would 
interfere with viral replication.6, 21, 22 Indeed, it has been 
demonstrated that the N7-methylation of flaviviral RNA cap 
structure is essential for viral mRNA translation into protein, 
whereas the 2’-O methylation is a “marker of self” limiting the 
detection of viral RNA by the host innate immune sensors of the 
RIG-like family such as RIG-1 and MDA5.28, 29, 31 As such, the 
essential roles played by viral MTases during the viral life cycle 
demonstrate the great potential of these enzymes as viable targets 
for drug design. 
While the N-terminal domain of the NS5 protein is responsible 
for cap-MTase activities, the C-terminal domain of the protein is 
responsible for the RdRp activity.4, 32, 33 Unlike most polymerases 
flaviviral RdRp utilizes a de novo initiation mechanism, wherein a 
5’-triphosphate AG RNA dinucleotide is first synthesized by the 
polymerase, even in the absence of RNA template. This AG 
dinucleotide is next used by the polymerase as a primer for RNA 
polymerization.4, 32-34 Proper function of the RdRp is critical for 
flaviviral replication, thus, impeding the ability of RdRp to 
synthesize viral RNA is also an attractive target for drug design. 
Furthermore, a therapeutic that could disrupt both the MTase 
activity as well as the RdRp activity of the NS5 protein could 
prove to be a highly effective broad-spectrum inhibitor for the 
treatment of numerous flaviviruses. 
Unfortunately, there are currently no FDA approved 
therapeutics for treating flaviviruses infections.8, 19 Similarly, 
vaccine development for flaviviruses has been challenging, 
especially for DENV due to the necessity to provide a vaccine that 
would be effective against all four serotypes8, 35, 36 Furthermore, if 
a serotype of DENV is not fully protected against, a patient is more 
likely to develop severe Dengue hemorrhagic fever or Dengue 
shock syndrome.35, 36 As such, broad spectrum therapeutics are 
needed in order to better combat these viral infections. 
Recent studies have focused on either developing novel 
therapeutics or repurposing previously approved drugs in order to 
expedite the development process.7, 8, 37-40 Of these therapeutics, 
nucleoside analogues initially garnered much attention due to their 
ability to disrupt the function of important viral replication 
enzymes.38, 41 One example of a potent nucleoside analogue is 
NITD008 (Figure 3), an adenosine mimic that has demonstrated 
the ability to inhibit the RdRp domain of all four serotypes of 
DENV with an average EC50 value of 0.64 µM.5, 38, 42 While these 
initial studies were promising, various studies found that NITD008 
is not a viable option for prophylaxis against DENV, as preclinical 
studies have demonstrated cytotoxicity associated with NITD008 
treatment.5, 38 
 
Another example is Sinefungin (Figure 3), a natural SAM/SAH 
mimic that has demonstrated potent antiviral activity against 
numerous viral MTases, including those of flaviviruses with an 
IC50 value of 0.03 µM against N7 methylations and 0.041 µM 
against 2’-O-methylations in DENV.42, 43 Unfortunately, 
Sinefungin has not been pursued further as a flavivirus therapeutic 
due to its low selectivity for viral MTases verses human 
MTases.37,43 While these analogues ultimately proved ineffective 
as potential therapeutics, they demonstrated the potential scope for 
utilizing nucleoside analogues in anti-flavivirus therapeutics. 
Figure 1.General structure of the flavivirus genome including 5’ 
and 3’ untranslated regions and the polyprotein processing of both 
the structural and nonstructural protein regions.17-18 



















Figure 3. Early examples of antiflaviviral nucleoside inhibitors. 
Over the past two decades, the Seley-Radtke lab has focused on 
developing flexible purine base nucleoside analogues termed 
“fleximers”.44-57 These compounds feature a purine ring that is 
“split” into the imidazole and pyrimidine moieties, with a single 
carbon-carbon bond between the C4 of the imidazole and the C5 
of the pyrimidine (proximal fleximers), or the C5 of the imidazole 
and the C6 of the pyrimidine (distal fleximers) (Figure 4)44-47 
These nucleoside analogues retain the hydrogen bonding and 
stacking elements necessary for nucleoside recognizing enzymes, 
while allowing for alternative interactions in the enzyme binding 
site.44-47, 49-51 This inherent flexibility allows for free rotation 
around the carbon-carbon bond between the imidazole and 
pyrimidine rings, thereby increasing the rotational degrees of 
freedom and allowing the fleximer to interact with other binding 
site moieties that were previously unattainable by the parent purine 
nucleoside.46, 47, 49-51 Due to these interesting characteristics, the 
Seley-Radtke lab has recently applied the fleximer approach to 
FDA-approved nucleoside inhibitors in order to create more potent 
analogues for antiviral therapeutics. Acyclovir (ACV), for 
example, is an FDA-approved acyclic nucleoside analogue mainly 
used to treat herpes simplex virus and varicella zoster virus 
infections.58-60 
Previously, fleximer analogues were synthesized utilizing the 
sugar moiety found in ACV, where broad spectrum screening of 
the Flex-ACV analogues revealed compound 1 to be active (10.1 
µM) against HCoV-NL63, an endogenous strain of human 
coronavirus (CoV) that displays similar symptoms to the common 
cold.53 Further analysis of compound 1 and its acetylated prodrug 
1-Ac (Figure 5) demonstrated low micromolar in vitro antiviral 
activity against both Severe Acute Respiratory Syndrome (SARS) 
and Middle East Respiratory Syndrome (MERS) - two deadly 
human coronaviruses for which there is currently no cure. 
Compound 1-Ac exhibited activity against MERS at 3.4 µM (in 
Vero) and 11.9 µM against SARS, while 1 inhibited HCoV-NL63 
at 8.8 µM. These findings were ground-breaking since these 
compounds were the first nucleoside analogues to exhibit low 
micromolar levels of anti-coronavirus activity.53 
These promising results prompted further investigation of these 
analogues against other viruses such as filoviruses, particularly 
given the dual anti-CoV and anti-Ebola activity recently noted by 
the nucleoside analogue Remdesivir.61, 62 In vitro antiviral testing 
revealed that compound 1, 1-Ac, and the phosphoramidate prodrug 
1-MG were all active against Ebola (EBOV) virus, with 
compound 1 exhibiting the greatest activity (EC50 = 2.2 ± 0.3 
µM).54 These results were quite interesting as they suggest the 
potential for dual activity for compound 1 and 1-Ac against both 
CoVs53 and EBOV.54 Further studies also revealed promising anti-
EBOV activity for compounds 2 and 2-Ac, with the acetylated 
analogue 2-Ac demonstrating an EC50 value of 8.2 ± 1.8 µM 
(unpublished data). 
Due to the remerging prevalence of DENV and ZIKV 
throughout the world, the ability of the Flex-ACV compounds to 
inhibit those viruses was pursued. Congruently, the compounds 
were also analyzed further in an effort to elucidate their 
mechanism of action as well as to explore the design of more 
potent compounds. Herein, the synthesis, antiviral activity against 
both DENV and ZIKV, and biological studies designed to uncover 




The compounds for this study were chosen based on the 
previous results for compounds 1, 1-Ac, and 1-MG against MERS, 
SARS,53 and EBOV,54 as well as unpublished results for 
compound 2 and 2-Ac against EBOV. The previously reported 
organometallic coupling procedures used by our group53, 54 to 
couple the two heterocyclic moieties involved tedious and multiple 
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Figure 5. Structure of the target fleximer analogues compared to the parent analogue Acyclovir. 
purification processes to remove the tin from the Stille coupling 
methodology, which led to very poor yields. As a result, attention 
turned to the Suzuki coupling methodology, which resulted in 
much cleaner reactions, facile purifications, as well as greatly 
improved yields. Starting with Scheme 1, coupling the imidazole 
to the commercially available 2-[(acetyloxy)methoxy]ethyl 
acetate (3) using BSA and TMS-triflate gave 4, which, following 
selective deiodination, gave iodoimidazole 5.54 
Compound 9 was synthesized starting with commercially 
available 2-amino-4-chloro-6-methoxypyrimidine for series 1 
(Scheme 2).63 Similarly, compound 10 was synthesized starting 
with commercially available 2,4-dimethoxypyrimidine for series 
2.64 Subsequent Suzuki-Miyaura cross-coupling of 9 and 5 gave 1 
(30% over two steps), and coupling of 10 with 5 provided 2 (48% 
over two steps) (Scheme 2), each by way of 11 or 12 as the in-situ 
intermediate for the modified Suzuki-Miyaura couplings.63 
Compounds 1 and 2 were then used to synthesize the acetate 
protected prodrugs 1-Ac and 2-Ac respectively (Scheme 2).65 
Synthesis of the phosphoramidate prodrugs 1-MG and 2-MG 
began with commercially available L-alanine and utilized 
procedures previously described by our lab54 as well as those found 
in the literature66 to yield the 2- ethylbutyl 
((perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate inter-
mediate 13 (Scheme 3). Reaction of this intermediate with either 
1 or 2 and tert-butyl magnesium chloride afforded the 
phosphoramidate prodrugs 1-MG and 2-MG as diastereomeric 
mixtures in moderate yields (74% and 86% respectively). 
Finally, synthesis of the triphosphate analogues 1-TP and 2-TP 
were accomplished using a modified procedure by Hollenstein et. 
al. which utilized SalPCl and tributylammonium pyrophosphate.67 
The methodology developed by Hollenstein et. al. noted important 
differences that ultimately greatly increased overall yields. For 
instance, prior to the reaction it is important that the fleximer 
nucleoside be coevaporated with anhydrous pyridine then dried in 
vacuo overnight, instead of storing the fleximer nucleoside in dried 
pyridine, 1,4-dioxane, and molecular sieves overnight. 
Furthermore, proper handling of 2-chloro-1,3,2-benzo-
dioxaphosphorin-4-one (SalPCl) is important. SalPCl is a 
commercially available reagent that is typically a glassy green 
solid, however, once exposed to moisture, develops a powdery 
white coating on the outside of the crystals that should be scraped 
13
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Scheme 3. Reagents and conditions: (a) 1 or 2, tBuMgCl, THF, rt, overnight. 





















Scheme 2. Reagents and conditions: (a) DIPEA, 10% Pd/C, H2, rt, 4 h; (b) NBS, CHCl3, rt, dark, 5 h; (c) Br2, NaHCO3, 50% MeOH, rt, 3 h; (d) 
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off prior to addition or the reaction goes poorly. Finally, in order 
to maximize the yield, HPLC purification should be done 
immediately to make the entire purification process more facile. 
Synthesis of the triphosphate analogues 1-TP and 2-TP began 
with the addition of SalPCl to the fleximer scaffold to give a 
phosphite intermediate (Scheme 4).67 Then, addition of 
tributylammonium pyrophosphate and tributylamine induced 
cyclization of the phosphate moieties. After stirring at room 
temperature for 45 minutes, I2 and water were added to the reaction 
mixture in order to promote the oxidation of the α phosphorous 
from a P(III) to a P(V) center.66 Finally, the excess iodide was 
quenched with 10% sodium thiosulfate and the crude reaction was 
purified via HPLC to give either 1-TP or 2-TP. Following 
purification, triphosphates 1-TP and 2-TP were obtained as the 
triethylamine salts. As the triethylamine salts were not suitable for 
the enzymatic assays, these compounds were converted to their 
sodium salt forms using a Dowex 50Wx2 Na+ ion exchange 
column. This produced both triphosphates in good yields (50% for 
1-TP and 62% for 2-TP). We have repeated this approach 
numerous times now and the yields have stayed consistent.  
2.2 Antiviral Activity 
The potent antiviral activity demonstrated by compounds 1, 1-
Ac, and 1-MG against a wide array of viruses including SARS-
CoV,53 MERS-CoV,53 as well as filoviruses such as EBOV54 
prompted further investigation with these analogues against 
additional viruses. These analogues, as well as the dimethoxy 
analogues 2 and 2-Ac, were then screened against various 
flaviviruses including DENV, ZIKV, and YFV. The analogues 
were analyzed utilizing a visual cytopathic effect assay on Vero76 
cells infected with the live-virus isolates of DENV (New Guinea 
C), ZIKV (MR766), and YFV (17D). 
The results showed that several flex-analogues demonstrated 
moderate to potent antiviral activity against all the flaviviruses 
tested, with compound 1 demonstrating the greatest antiviral 
activity against DENV (EC50 = 0.057 µM) (Table 1). Compound 1 
also demonstrated potent antiviral activity against YFV (EC50 = 
0.37 µM) with a selective index (SI) of 4.6. Although this is not 
ideal, preliminary minimum tolerated dose (MTD) studies have 
revealed no toxicity up to 250 mgs/kg, and we are currently 
pursuing those studies further to also explore the ProTide 
analogues.  
A significant decrease in toxicity was observed with the acetate 
protected analogue 1-Ac against DENV compared to the parent 
analogue 1 (CC50 = 65 µM and CC50 = 1.2 µM respectively), 
however, a decrease in activity was also observed as 1-Ac 
demonstrated an EC50 of 6.1 µM. While not as potent as compound 
1, compound 2-Ac demonstrated moderate activity against DENV 
with an EC50 of 19 µM, and little associated cytotoxicity. None of 
the analogues tested demonstrated any antiviral against ZIKV, and 
only analogue 1 demonstrated activity against YFV. 
These results suggest that compound 1 could potentially act as 
a broad spectrum antiviral therapeutic across a wide range of viral 
families including coronaviruses, filoviruses, and now 
flaviviruses. 
2.3 Inhibition NS5 activities: RdRp and MTase Activity 
As many nucleotide analogues act as chain terminators or 
mutagenic nucleotides incorporated into RNA, 1-TP and 2-TP 
were tested for their ability to be incorporated into RNA using 
DENV RdRp. No direct inhibition was observed at concentrations 
below 200 µM, however when studied for incorporation, as shown 
in Figure 6 on the next page, 1-TP did not serve as a competitive 
inhibitor in the presence of GTP. Compound 1-TP did, however, 
act as a delayed chain terminator. As there was no incorporation, 
but chain termination did occur, we then speculated that this was 
due to an allosteric inhibition, likely due to inhibition of a different 



























1, X = NH2
2, X = OCH3
1-TP, X = NH2
2-TP, X = OCH3
1-TP, 51%
2-TP, 62%
Scheme 4. Reagents and conditions: (a) i. 1 or 2, SalPCl, Pyr, 1,4-dioxane, rt, 45 min; ii. tributyl ammonium pyrophosphate, tributylamine, 
DMF, rt, 45 min; iii. I2, H2O, Pyr, rt, 30 min. 
 
Table 1. Antiviral activity of flex-analogues against various flaviviruses including Dengue (DENV), Zika 
(ZIKV), and Yellow Fever Virus (YFV) in Vero76 cells.  
Compound DENV ZIKV YFV aEC50 bCC50 EC50 CC50 EC50 CC50 
1 0.057 1.20 >1.80 >1.80 0.37 1.7 
1-Ac 6.1 65 >100 >100 >57 57 
1-MG >57 57 >31 31 >55 55 
2 >50 50 >76 76 >58 58 
2-Ac 19 53 79 >100 >58 58 
2-MG >53 53 >56 56 >53 53 
Values are reported in µM. aEC50: effective concentration showing 50% inhibition of virus-induced CPE. bCC50: cytotoxic 
concentration showing 50% inhibition of cell survival. 
In that regard, as mentioned previously, the MTase activity for 
flavivirus NS5 is an interesting and important target for the 
development of antiviral therapeutics. In the flaviviruses, the 
MTases and RdRp are in the same protein complex. However, 
unlike viral RdRps, which demonstrate a high mutation rate68, 69, 
the viral MTase structure is highly conserved across most 
flavivirus species,21, 70 making viral MTases an attractive target for 
drug design. As such, compounds 1, 1-Ac, 1-MG, and 1-TP were 
analyzed for activity against DENV, ZIKV, and human N7 
MTases utilizing a radioactive filter-binding assay (Figure 7). The 
inhibition of the 2’-O-MTase activity of DENV and ZIKV, and 
that of the human N7 (RNMT) MTases was first analyzed against 
50 µM of compound. Briefly, the MTases were incubated with 
synthetic RNA substrates (GpppAC5), radioactive 3H-SAM, and a 
Flex-analogue at 30°C for 30 minutes.27 The reaction products 
were then filtered on DEAE membranes and the radioactivity 
transferred on the RNA was quantified. Sinefungin was utilized as 
inhibitory control due to its known inhibition of both viral and 
human MTases.37, 42, 43 
While compound 1 did not exhibit a significant inhibitory effect 
on the different MTases activities, the triphosphate form 1- TP 
inhibited both DENV MTase and ZIKV MTase at 34% and 12% 
respectively (Figure 7). The triphosphate analogue 2-TP 
demonstrated the greatest inhibitory activity against ZIKV MTase 
at 9%. Furthermore, none of the analogues tested inhibited human 
N7 MTase activity, which also suggests these analogues 
selectively inhibit viral MTases. 
Analogues 1-TP and 2-TP were then further analyzed in order 
to determine IC50 values against the MTases (Table 2). This data 
was congruent with the previous MTase data where compounds 1-
TP and 2-TP demonstrated a greater inhibitory effect against 
ZIKV MTase compared to DENV MTase. The triphosphate 2-TP 
was most potent against ZIKV MTase (0.15 µM) whereas the 
triphosphate 1-TP (IC50 = 1.7 µM) was still active against ZIKV 
MTase but to a lesser degree than 2-TP. This data suggests that the 
antiviral activity seen with compound 1 is due to inhibition of the 
MTase activity rather than inhibition of the viral polymerases, 
since nucleosides must first be converted by kinases to the 
corresponding triphosphates in order to be active against and/or 
recognized. 
2.4 Computational Molecular Modeling Studies 
In order to gain further insights on the mechanism of action of 
the fleximers, their predicted binding to DENV (PDB ID 4V0R), 
ZIKV (PDB ID 5G0Z), YFV (PBD ID 3EVD), and human N7 
(PDB ID 5E9W) MTase crystal structures were evaluated using a 
series of docking simulations. In particular, the capt/GTP binding 
Figure 7. Percent inhibition of ZIKV and DENV MTase by series 1 and 2 (50 µM). None of the compounds inhibited human N7 MTase, 
suggesting that these analogues selectively inhibit the viral MTases. 
 
Table 2. Inhibition of MTase activity of compounds 1-TP and 2-TP against DENV NS5-MTase, ZIKV NS5-MTase, and human 
N7 MTase. 





1-TP 1.7 µM 8.4 µM 49 µM 
2-TP 0.15 µM 1.1 µM 13 µM 
 
Figure 6. Incorporation of 1-TP into the DENV genome, in the 
absence of GTP. An elongation complex was formed of DENV NS5 
and a primer/template combination corresponding to the 5’ end of 
DENV2 genome and the 3’end of the antigenome. Substrate (P10) and 
product bands were visualized by autoradiography, and quantification 
of primer [P10] illustrates inhibition of RNA synthesis. 
 
site of these enzymes was explored since the triphosphates 1-TP 
and 2-TP were the most active against both ZIKV and DENV 
MTases. Furthermore, as this binding site is highly conserved 
among flaviviruses,70 it was hypothesized that if the fleximers 
efficiently bind in this site, they could potentially serve as broad 
spectrum inhibitors. 
As shown in Figure 8A, 1-TP is predicted to maintain most of 
the key hydrogen bonding and stacking interactions shown by GTP 
in the ZIKV MTase structure demonstrating a very similar spatial 
occupation of the pocket overall. Notably, the hydrogen bonding 
between the free amine group of the fleximer with Met19 and 
Leu16 as well as between the oxygen in the sugar moiety of the 
fleximer and Lys13 of the enzyme binding site appears to be 
similar to the corresponding groups in GTP.   
The triphosphate analogue 2-TP was also analyzed (Figure 8B), 
in order to assess the potential effect of the replacement of the free 
amine at the 2-position with a methoxy group on binding to the 
ZIKV MTase. According to the docking results obtained, this 
modification is associated with the potential loss of hydrogen 
bonding with the backbone of Met19 and Leu16. However, the 
flex-nucleobase was still oriented such a way that it interacted with 
Phe24. In the case of both 1-TP and 2-TP, the triphosphate moiety 
was placed in the same region observed for GTP, and overall both 
compounds were predicted to occupy the pocket in a similar 
fashion to GTP. 
While the ZIKV MTase GTP binding site shows the presence 
of an alanine at position 21, the residue in the corresponding 
position is replaced by an arginine (Arg22) within DENV-3 and 
DENV-4, and by a lysine (Lys22) in DENV-1 and DENV-2 
(Figure 9A, DENV-3, PDB ID 4V0R). The arginine (or lysine) 
lateral chain allows for an additional hydrogen bond with the 
methoxy group of compound 1-TP, which could potentially 
explain its increased antiviral activity against DENV compared to 
ZIKV. When compared to the binding interactions found with 1-
TP, 2-TP also displayed similar potential hydrogen bonding 
interaction between the 4-methoxy group and Arg22. As seen for 
ZIKV MTase, the replacement of the amine group in 1-TP with 
the methoxy group in 2-TP led to a loss of hydrogen bond 
formation with Leu17 and Leu20 (Figure 9B). Moreover, the 
overall binding of both 1-TP and 2-TP was consistent with the 
conformation observed for co-crystallized GTP. In summary, the 
molecular modeling results obtained for both ZIKV and DENV 
MTases are in accordance with the experimental data found in the 
enzymatic MTase assay. The lack of significant antiviral activity 
displayed by 2-TP could also be explained by poor 
phosphorylation of the parent fleximer analogue to its triphosphate 
form, likely due to the role of the nucleobase amine group in 
substrate recognition by the phosphorylating enzymes. 
Similar to the DENV-1 and DENV-2 MTase binding sites, the 
YFV GTP MTase binding site (PDB ID 3EVD) showed the 
presence of a lysine residue, Lys21, in proximity to the nucleobase 
subsite of co-crystallized GTP. The results of the simulations 
revealed that the triphosphate 1-TP is still predicted to maintain 
key hydrogen bonding interactions with Leu19 and Leu16. 
However, unlike the DENV-3 binding site, the Lys21 lateral chain 
does not appear to be at an optimum distance to interact with the 
4-methoxy group (Figure 10A). This supports the decrease in 
activity seen with compound 1 against DENV and YFV (0.057 µM 
compared to 0.37 µM). By comparison, 2-TP is unable to form 
any substantial hydrogen bonding interactions with Leu19, Leu16, 
or Lys21 (Figure 10B). 
Figure 8. Predicted binding of A) 1-TP (carbon atoms in light blue) and B) 2-TP (carbon atoms in pink) to the GTP pocket of ZIKV NS5 
MTase (PDB ID 5G0Z). Co-crystallized GTP is shown in light grey. 
 
Figure 9. Predicted binding of A) 1-TP (carbon atoms in light blue) and B) 2-TP (carbon atoms in pink) to the GTP pocket of DENV NS5 
MTase (PDB ID 4V0R). Co-crystallized GTP is shown in light grey. 
 
Finally, the potential interactions between the fleximer 
triphosphate analogues and the human mRNA cap guanine-N7 
GTP binding site were analyzed (PDB ID 5E9W; GTP coordinates 
as defined in the E. cuniculi Ecm1 crystal structure 1RI1). The 
GTP binding pocket of human N7 MTase is significantly different 
from the one found in flaviviruses: it more closely resembles the 
SAM/SAH binding site and possesses a different amino acid 
residue composition. In line with the experimental data obtained, 
1-TP was not predicted to have strong binding interactions in this 
site, even though the fleximer can adopt a similar general 
orientation in comparison with the natural ligand GTP (Figure 
11A). The flex-nucleobase occupied a larger region of space than 
that defined by the GTP guanine moiety, and the residues 
surrounding this region of the pocket do not participate in an H-
bond interactions. Moreover, there are no other notable 
interactions with the flex-nucleobase of the scaffold, thus 
supporting the experimental data observed for the reduced 
inhibition of this enzyme. In contrast, docking results in the GTP 
binding pocket of human N7 MTase would suggest a better 
interaction of 2-TP to this enzyme in comparison with 1-TP, as 
the presence of the two methoxy groups appear to allow formation 
of a hydrogen bond with Asn176 (Figure 11B). 
3. Conclusions 
The design and synthesis of new and more effective antiviral drugs 
is of critical importance to the biomedical field in order to treat 
viruses such as flaviviruses. While ongoing studies have identified 
various therapeutics as potential treatments for diseases caused by 
flaviviruses, there are currently no FDA approved vaccines (except 
for YFV, however this vaccine has been associated with serious 
adverse effects71) or treatment, and as such, it is critical that an 
effective treatment option is developed. The flex-analogues 
reported in this study have demonstrated moderate activity against 
various flaviviruses, with analogue 1 being most active against 
DENV and YFV. While the mechanism of action has yet to be 
fully elucidated, these preliminary studies have shown that 
compound 1-TP inhibits the DENV and ZIKV MTases with IC50 
values of 8.4 µM and 1.7 µM respectively, potentially by binding 
in the GTP binding site of this enzyme. These results are promising 
due to the highly conserved nature of flavivirus MTases. Further 
research is currently underway in order to fully elucidate their 
mechanism(s) of action as well as to screen these analogues 
against other flaviviruses such as West Nile Virus and Tick-Borne 
Encephalitis, in order to see if these analogues could serve as 
broad-spectrum treatments against additional flaviviruses. 
4. Experimental 
4.1 Chemical Synthesis 
General Information: All reactions were performed using oven-
dried glassware under a nitrogen atmosphere with magnetic 
stirring. Reagents were purchased from Sigma-Aldrich, Alfa 
Aesar, and Combiblocks. Solvents were either purchased as 
anhydrous or were dried using the MBRAUN solvent purification 
system (MB-SPS). Reactions were monitored by thin layer 
chromatography (TLC) using EMD silica gel 60 F254 coated 
glass-backed TLC plates and visualized with a UV lamp and/or 
KMnO4 stain. Column chromatography was performed on a 
Figure 10. Predicted binding of A) 1-TP (carbon atoms in light blue) and B) 2-TP (carbon atoms in pink) to the GTP pocket of YFV NS5 
MTase (PDB ID 3EVD). Co-crystallized GTP is shown in light grey. 
 
Figure 11. Predicted binding of A) 1-TP (carbon atoms in ight blue) and B) 2-TP (carbon atoms in pink) to the GTP pocket of human mRNA 
cap guanine-N7 MTase GTP binding site (PDB ID 5E9W). GTP is shown in light grey. 
 
Combiflash®Rf automated chromatography using REdiSep Rf 
silica. High Pressure Liquid Chromatography (HPLC) purification 
was performed on an LC-8A Shimadzu preparation liquid 
chromatograph using a Zorbax SB C18 column 9.4x250 mm, 5 
µm. Samples were lyophilized utilizing a Labconco Freezone 1 L 
lyophilizer. 1H NMR spectra was recorded on a JOEL Eclipse 
ECX (400 MHz) spectrometer. Chemical shifts are reported in 
parts per million (δ ppm) from tetramethylsilane with the solvent 
resonance as an internal standard. Data for the 1H NMR are 
reported as follows; br = broad, s = singlet, d = doublet, t = triplet, 
q = quartet, dd = doublet of doublets, m = multiplet. 13C NMR were 
recorded on a JOEL Eclipse ECX (126 MHz) or a Bruker Advance 
III HD (101 MHz) spectrometer with complete proton decoupling. 
Data for 13C NMR are reported in terms of chemical shifts (δ ppm) 
with the solvent resonance as the internal standard. 31P NMR was 
recorded on a JOEL Eclipse ECX (162 MHz) spectrometer with 
complete proton decoupling using 85% phosphoric acid as an 
external standard. Data for 31P NMR are reported in terms of 
chemical shift (δ ppm) (multiplicity, integration), with 
multiplicities reported the same as for 1H NMR. Mass 
spectrometry was performed on a Bruker AmaZon X quadrupole 
ion trap mass spectrometer using electrospray  ionization (ESI). 
The purity of all compounds tested in biological assays were 
verified by elemental analyses performed by Atlantic Microlabs. 
4.1.1. Synthesis of 2-((4,5-diiodo-1H-imidazol-1-yl)methoxy)ethyl 
acetate (4). 
4,5-diiodoimidazole (10.0 g, 31.25 mmol) was suspended in 
anh. Acetonitrile (200 mL) under nitrogen and stirred at room 
temperature for 10 mins. Then bis(trimethylsilyl)acetamide (46.0 
mL, 187.68 mmol) and 3 (6.0 mL, 37.46 mmol) were added and 
the solution was allowed to stir at room temperature under direct 
nitrogen bubble for 4 hours. Trimethylsilyl 
trifluoromethanesulfonate (8.2 mL, 47.22 mmol) was then added 
slowly dropwise over 5 minutes. The reaction was then heated to 
80°C under direct nitrogen bubble for 18 hours. After cooling to 
room temperature, the reaction was cooled further in a salt/ice bath 
to 0°C and quenched with NaHCO3 (100 mL). After stirring for 10 
minutes, the reaction was extracted 5x with CH2Cl2 (200 mL). The 
combined organic layers were dried with MgSO4, gravity filtered, 
and the solvent was removed in vacuo to afford an amber oil with 
yellow solid. The crude mixture was then purified by flash column 
chromatography on silica gel (40-80% EtoAc in Hexanes) to give 
the pure product as a white solid with yellow oil (9.5 g, 70%); Rf 
= 0.39 (1:1 EtOAc/Hexanes); 1H NMR (400 MHz, CDCl3) δ 7.61 
(s, 1H), 5.18 (s, 1H), 3.93-3.95 (t, J = 4.6 Hz, 2H), 3.45-3.47 (t, J 
= 4.6 Hz, 2H), 1.82 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 170.67, 
142.06, 97.32, 82.71, 77.93, 66.69, 62.76, 21.07; MS (ESI+) m/z 
calc for C8H10I2N2O3 [M+H+]: 436.99, found: 436.9. 
4.1.2. Synthesis of 2-((4-iodo-1H-imidazole-1-yl)methoxy)ethan-
1-ol (5). 
To a solution of compound 4 (5.6 g, 12.87 mmol) in 30% EtOH 
and H2O (125 mL total volume) was added Na2SO3 (8.17 g, 64.82 
mmol). The solution was then refluxed at 120°C for 18 hours. 
After cooling to room temperature, the reaction was concentrated 
in vacuo to remove the EtOH and was extracted 4x with CH2Cl2. 
The combined organic layers were dried with MgSO4 and gravity 
filtered. The solvent was removed in vacuo to afford a white solid. 
The crude product was then purified by flash column 
chromatography on silica gel (0-20% CH3OH in CH2Cl2) to give 
the pure product as a white solid (2.73 g, 79%); Rf = 0.79 (1:3 
CH3OH/CH2Cl2); 1H NMR (400 MHz, DMSO-d6) δ 7.74 (s, 1H), 
7.46 (s, 1H), 5.31 (s, 2H), 4.65-4.68 (t, J = 10.5 Hz, 1H), 3.42-3.47 
(m, 2H), 3.35-3.37 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 
140.5, 125.5, 83.4, 76.2, 70.7, 60.3; MS (ESI+) m/z calcd for 
C6H9IN2O2 [M+H+]: 269.05, found 269.0. 
4.1.3. Synthesis of 4-methoxypyrimidine-2-amine (7). 
Commercially available 2-amino-4-chloro-6-methoxy-
pyrimidine (8.0 g, 50.13 mmol) was suspended in 3:2 EtOAc: 
CH3OH (175 mL total volume). After addition of 
diisopropylethylamine (18 mL, 100.25 mmol) and 10% Pd/C (1.6 
g, 20% w/w), the reaction was mixed on a hydrogenator for 4 
hours. Upon completion, the reaction was filtered over a celite pad, 
washed with EtOAc (100 mL), and the solvent was removed in 
vacuo to give a pale yellow/white solid. The crude product was 
then purified by flash column chromatography on silica gel (40-
80% EtOAC in Hexanes) to give the pure product as a white solid 
(5.3 g, 85%); Rf = 0.34 (1:1 EtOAc/Hexanes); 1H NMR (400 MHz, 
DMSO-d6) δ 7.90-7.91 (d, J = 5.5 Hz, 1H), 6.52 (s, 2H)5.94-5.95 
(d, J = 5.5 Hz, 1H), 3.74 (s, 3H); 13C NMR (126 MHz, DMSO-d6) 
δ 170.16, 164.08, 158.99, 96.58, 53.25; MS (ESI+) m/z calcd for 
C5H7N3O [M+H+]: 126.13, found 126.2. 
4.1.4. Synthesis of 5-bromo-4-methoxypyrimidin-2-amine (9). 
To a solution of compound 7 (1.5 g, 11.99 mmol) in chloroform, 
N-bromosuccinimide (2.14 g, 11.99 mmol) was added. After 
stirring in the dark for 5 hours, the solution was added to CH2Cl2 
(200 mL) and 1M NaOH (100 mL). Upon mixing the layers were 
separated and the organic layer was washed with brine (100 mL). 
The organic layer was then dried with MgSO4 and gravity filtered. 
The solvent was removed in vacuo to afford a yellow/white solid. 
The crude product was then purified by flash column 
chromatography on silica gel (0-5% CH3OH in CH2Cl2) to give the 
pure product as a fluffy white solid (2.4 g, 95%); Rf = 0.59 (1:1 
EtOAc/Hexanes); 1H NMR (400 MHz, DMSO-d6) δ 8.05 (s, 1H), 
6.78 (s, 2H), 3.83 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 
165.17, 162.91, 159.48, 91.02, 54.44; MS (ESI+) m/z calcd for 
C5H6BrN3O [M+]: 204.03, found: 204.0. 
4.1.5. Synthesis of 5-bromo-2,4-dimethoxypyrimidine (10). 
NaHCO3 (2g, 23.81 mmol) was slurried with compound 8 (1.74 
mL, 14.27 mmol) in 50% CH3OH in water (45mL total volume). 
Br2 (1.32 mL, 25.69 mmol) was added dropwise over 1 hour with 
stirring. After 30 minutes of Br2 addition, additional NaHCO3 (3.5 
g, 41.66 mmol) was added and the reaction mixture was stirred at 
room temperature for 2 hours. The resulting white precipitate was 
vacuum filtered and washed with CH3OH (20 mL) and dried under 
vacuum to give the product as a shiny white solid (2.12 g, 68%); 
Rf = 0.97 (1:1 EtOAc/Hexanes); 1H NMR (400 MHz, CDCl3) δ 
8.28 (s, 1H), 4.03 (s, 3H), 3.96 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 166.86, 164.36, 159.23, 98.26, 55.33, 55.00; MS (ESI+) 
m/z calcd for C6H7BrN2O2 [M+]: 219.04, found: 219.0. 
4.1.6. Synthesis of 2-((4-(2-amino-4-methoxypyrimidin-5-yl)-1H-
imidazol-1-yl) methoxy)ethan-1-ol (1). 
To a dry Schlenk flask, compound 9 (0.50 g, 2.45 mmol), 
bis(pinacolato)diboron (0.75 g, 2.94 mmol), and potassium acetate 
(0.72 g, 7.35 mmol), were added and suspended in dimethoxy 
ethane (50 mL). Then the solution was subjected to freeze-pump-
thaw cycles under N2 (3x). Tetrakis(triphenylphosphine)-
palladium(0) (0.30 g, 0.25 mmol) was added to the reaction flask 
and subjected to one more freeze-pump-thaw cycle. The reaction 
was then heated to 90°C overnight with stirring. The reaction was 
then cooled to room temperature and 5 (0.65 g, 2.45 mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.14 g, 0.12 mmol), 
and aqueous NaHCO3 (20 mL) were added. The flask was 
evacuated and pumped with N2 and heated to 90°C for 4 hours. 
After stirring, the reaction was cooled to room temperature and the 
solvent was removed in vacuo. The residue was suspended in CH-
2Cl2/CH3OH and NaHCO3 was gravity filtered away from the 
solution. Solvent was removed in vacuo to give the crude product 
as an orange oil. The crude product purified via flash column 
chromatography (0-10% CH3OH in CH2Cl2) to afford a yellow oil. 
The residue was then washed with minimal aqueous sodium 
thiosulfate and extracted with EtOAc 3-4x. The organic layer was 
dried with MgSO4, gravity filtered, and the solvent was removed 
in vacuo to give a pink solid. The product was further purified via 
flash column chromatography on silica gel (5-10% CH3OH in 
CH2Cl2) to afford the product as a light pink solid (0.19 g, 30%); 
Rf = 0.26 (1:9 CH3OH/CH2Cl2); 1H NMR (400 MHz, DMSO-d6) δ 
8.59 (s, 1H), 7.77 (s, 1H), 7.37 (s, 1H), 6.52 (s, 2H), 5.34 (s, 2H), 
4.64-4.66 (t, J = 11.0 Hz, 1H), 3.91 (s, 3H), 3.41-3.44 (t, J = 10.0 
Hz, 2H), 3.36-3.38 (t, J = 9.6 Hz, 2H); 13C NMR (126 MHz, 
DMSO-d6) δ 165.78, 162.24, 155.48, 138.08, 134.72, 117.18, 
104.65, 76.21, 70.39, 60.44, 53.67; MS (ESI+) m/z calcd for 
C11H15N5O3 [M+H+]: 266.27, found 266.2; Elemental analysis: 
Anal. Calcd for C11H15N5O3: C, 49.81; H, 5.70; N, 26.40. Found: 
C, 49.74; H, 5.76; N, 26.12. 
4.1.7. Synthesis of 2-((4-(2,4-dimethoxypyrimidine-5-yl)-1H-
imidazol-1-yl) methoxy)ethan-1-ol (2). 
To a dry Schlenk flask, compound 10 (0.50 g, 2.28 mmol), 
bis(pinacolato)diboron (0.69 g, 2.74 mmol), and potassium acetate 
(0.67 g, 6.84 mmol) were added and suspended in dimethoxy 
ethane (50 mL). Then the solution was subjected to freeze-pump-
thaw cycles under N2 (3x). Tetrakis(triphenylphosphine)-
palladium(0) (0.26 g, 0.22 mmol) was added to the reaction flask 
and subjected to one more freeze-pump-thaw cycle. The reaction 
was heated to 90°C overnight with stirring. The reaction was then 
cooled to room temperature and 5 (0.61 g, 2.28 mmol), 
tetrakis(triphenylphosphine)palladium(0) (0.13 g, 0.11 mmol), 
and aqueous NaHCO3 (20 mL) were added. The flask was 
evacuated and pumped with N2 and heated to 90°C for 4 hours. 
After stirring, the reaction was cooled to room temperature and the 
solvent was removed in vacuo. The residue was suspended in 
CH2Cl2/CH3OH and NaHCO3 was gravity filtered away from the 
solution. Solvent was removed in vacuo to give the crude product 
as a yellow solid with a yellow oil. The crude product was purified 
via flash chromatography on silica gel (0-5% CH3OH in CH2Cl2) 
to afford the product as a white solid (0.31 g, 48%); Rf = 0.38 (1:9 
CH3OH/CH2Cl2); 1H NMR (400 MHz, CD3OD) δ 8.77 (s, 1H), 
7.87 (s, 1H), 7.63 (s, 1H), 5.44 (s, 2H), 4.10 (s, 3H), 3.98 (s, 3H), 
3.62-3.64 (t, J = 9.1 Hz, 2H), 3.51-3.64 (t, J = 9.6 Hz, 2H); 13C 
NMR (126 MHz, CD3OD) δ 167.13, 163.70, 154.60, 137.89, 
133.13, 118.77, 108.89, 76.54, 70.07, 60.57, 54.08, 53.48; MS 
(ESI+) m/z calcd for C12H16N4O4 [M+H+]: 281.28, found: 281.2; 
Elemental analysis: Anal. calcd for C12H16N4O4: C, 51.42; H, 5.75; 
N, 19.99. Found: C, 50.99; H, 5.68; N, 19.72. 
4.1.8. Synthesis of 2-((4-(2-amino-4-methoxypyrimidin-5-yl)-1H-
imidazol-1-yl)methoxy)ethyl acetate (1-Ac). 
Compound 1 (0.050 g, 0.19 mmol) was suspended in anh. DMF 
(2 mL) and treated with acetic anhydride (0.053 mL, 0.56 mmol) 
and dimethylaminopyridine (0.0023 g, 0.019 mmol). The reaction 
was stirred at room temperature for 3 hours. After stirring, the 
solvent was removed in vacuo to give the crude product as a clear 
oil. The crude product was purified via flash column 
chromatography on silica gel (0-5% CH3OH in CH2Cl2) to afford 
the product as a light pink solid (0.040 g, 70%); Rf = 0.28 (1:9 
CH3OH/CH2Cl2); 1 H NMR (400 MHz, CD3OD) δ 8.54 (s, 1H), 
7.48 (s, 1H), 5.40 (s, 2H), 4.13-4.15 (t, J = 9.6 Hz, 2H), 4.00 (s, 
3H), 3.64-3.66 (t, J = 9.6 Hz, 2H), 1.96 (s, 3H); 13C NMR (126 
MHz, CD3OD) δ 171.27, 166.39, 161.86, 153.87, 137.44, 134.30, 
117.40, 104.76, 76.25, 66.53, 62.92, 52.78, 19.33; MS (ESI+) m/z 
calcd for C13H17N5O4 [M+H+]: 308.31, found: 308.2; Elemental 
analysis: Anal. calcd for C13H17N5O4 + 0.3% CH3OH: C, 50.18; H, 
5.78; N, 22.08. Found: C, 50.41; H, 5.79; N, 22.10. 
4.1.9. Synthesis of 2-((4-2,4-dimethoxypyrimidin-5-yl)-1H-
imidazol-1-yl)methoxy) ethyl acetate (2-Ac). 
Compound 2 (0.050 g, 0.18 mmol) was suspended in anh. DMF 
(2 mL) and treated with acetic anhydride (0.051 mL, 0.53 mmol) 
and dimethylaminopyridine (0.0022 g, 0.018 mmol). The reaction 
was stirred at room temperature for 3 hours. After stirring, the 
solvent was removed in vacuo to give the crude product as an 
orange oil. The crude product was purified via flash 
chromatography on silica gel (0-5% CH3OH in CH2Cl2) and placed 
on a vacuum pump overnight to afford the product as a peak 
colored solid (0.076 g, 86%); Rf = 0.41 (1:9 CH3OH/CH2Cl2); 1H 
NMR (400 MHz, CD3OD) δ 8.77 (s, 1H), 7.86 (s, 1H), 7.60 (s, 
1H), 5.42 (s, 2H), 4.13-4.16 (t, J = 9.2 Hz, 2H), 4.09 (s, 3H), 3.97 
(s, 3H), 3.66-3.68 (t, J = 9.6 Hz, 2H), 1.96 (s, 3H); 13C NMR (126 
MHz, CD3OD) δ 171.23, 167.09, 163.70, 154.62, 137.89, 133.19, 
118.70, 108.81, 76.32, 66.62, 62.92, 54.11, 53.50, 19.35; MS 
(ESI+) m/z calcd for C14H18N4O5 [M+H+]: 323.32, found: 323.2; 
Elemental analysis: Anal. calcd for C14H18N4O5 + 0.4% H2O: C, 
51.18; H, 5.79; N, 16.93. Found: C, 51.03; H, 5.75; N, 17.00. 
4.1.10. Synthesis of 2-ethylbutyl((2-((4-(2-amino-4-
methoxypyrimidin-5-yl)-1H-imidazol-1-yl)methoxy)-ethoxy)-
(phenoxy)phosphoryl)alaninate (1-MG). 
To a solution of 1 (0.04 g, 0.15 mmol) in anh. THF (3 mL) under 
a nitrogen atmosphere was added tertbutylmagnesium chloride 
(1M in THF, 0.24 mL, 0.24 mmol) dropwise, and the reaction was 
stirred at room temperature for 30 minutes. In a separated flask, 13 
(0.08g, 0.17 mmol) was suspended in anh. THF (4 mL) and added 
to the reaction vessel. The reaction was allowed to stir at room 
temperature under a nitrogen atmosphere overnight. After stirring 
overnight, the reaction was quenched with CH3OH (2 mL) and 
stirred for another 5 minutes before removal of solvent in vacuo. 
The crude mixture was then purified by flash column 
chromatography on silica gel (0-10% CH3OH in CH2Cl2) to give 
the pure product as a pink oil (0.06 g, 74% mix of diastereomers); 
Rf = 0.49 (1:9 CH3OH/CH2Cl2); 1H NMR (400 MHz, CD3OD) δ 
8.64 (s, 1H), 7.79-7.80 (d, J = 5.4 Hz, 1H), 7.49 (s, 1H), 7.26-7.30 
(m, 2H), 7.10-7.16 (m, 3H), 5.38-5.41 (app d, 2H), 4.13-4.22 (m, 
2H), 3.86-4.04 (m, 6H), 3.65-3.70 (m, 2H), 1.40-1.48 (m, 1H), 
1.27-1.35 (m, 7H), 0.82-0.86 (m, 6H); 13C NMR (126 MHz, 
CD3OD) δ 173.85, 166.46, 161.66, 153.50, 150.83, 137.48, 
134.14, 129.38, 124.72, 120.17, 120.10, 117.4, 104.86, 76.31, 
67.44, 67.38, 66.70, 65.69, 52.88, 50.51, 50.22, 40.41, 22.92, 
19.31, 19.25, 19.21, 19.14, 10.02; 31P NMR (162 MHz, CD3OD) δ 
4.39, 4.17; MS (ESI+) m/z calcd for C26H37N6O7P [M+H+]: 577.25, 
found: 577.3; Elemental analysis: Anal. calcd for C26H37N6O7P + 
1.3% CH3OH: C, 53.04; H, 6.88; N, 13.59. Found: C, 53.31; H, 
6.66; N, 13.35. 
4.1.11. Synthesis of 2-ethylbutyl ((2-((4-(2,4-dimethoxypyrimidin-
5-yl)-1H-imidazol-1-yl)methoxy)ethoxy)-(phenoxy)-
phosphoryl)alaninate (2-MG). 
To a solution of 2 (0.042 g, 0.15 mmol) in anh. THF (3 mL) 
under a nitrogen atmosphere was added tertbutylmagnesium 
chloride (1M in THF, 0.30 mL, 0.30 mmol) dropwise, and the 
reaction was stirred at room temperature for 30 minutes. In a 
separate flask, 13 was suspended in anh. THF (4 mL) and added to 
the reaction vessel. The reaction was allowed to stir at room 
temperature under a nitrogen atmosphere overnight. After stirring 
overnight, the reaction was quenched with CH3OH (2 mL) and 
stirred for another 5 minutes before removal of solvent in vacuo. 
The crude mixture was then purified twice by flash column 
chromatography on silica gel (0-10% CH3OH in CH2Cl2) to give 
the product as a yellow oil (0.075 g, 86% mix of diastereomers); 
Rf = 0.48 (1:9 CH3OH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 
8.96 (s, 1H), 7.58-7.60 (d, J = 5.9 Hz, 1H), 7.44-7.45 (d, J = 2.7 
Hz, 1H), 7.23-7.27 (m, 2H), 7.07-7.16 (m, 3H), 5.26-5.28 (app. d, 
2H), 4.13-4.21 (m, 2H), 3.92-4.05 (m, 8H), 3.72-3.82 (m, 1H), 
3.58-3.63 (m, 2H), 1.41-1.59 (m, 1H), 1.24-1.34 (m, 8H), 0.79-
0.84 (m, 6H); 13C NMR (126 MHz, CDCl3) δ 173.65, 166.94, 
163.72, 155.64, 150.67, 137.30, 134.72, 129.70, 125.03, 120.20, 
118.06, 109.32, 67.53, 65.66, 54.9, 54.16, 50.28, 40.25, 23.21, 
21.16, 11.03; MS (ESI+) m/z calcd for C27H38N5O8P [M+H+]: 
592.60, found: 592.3; Elemental Analysis: Anal. calcd for 
C27H38N5O8P + 1% CH3OH: C, 53.93; H, 6.79; N, 11.23. Found: 
C, 53.89; H, 6.55; N, 11.02. 
4.1.12. General procedure for triphosphate synthesis (1-TP and 
2-TP)66. 
Nucleoside 1 or 2 (0.3 g, 0.1 mmol) was coevaporated with anh. 
Pyridine and placed in a vacuum overnight. Simultaneously, 
tributylammonium pyrophosphate (0.13 mmol) was dried in a 
separate flask under vacuum overnight. The dry nucleoside was 
dissolved in anh. Pyridine (0.2 mL) and anh. 1,4-dioxane (0.4 mL) 
under a N2 filled balloon. Then 2-chloro-1,3,2-
benzodioxaphosphorin-4-one (0.12 mmol) was added and the 
reaction was stirred at room temperature for 45 minutes (Ensure 
that the white powder impurity is scraped off of the 2-chloro-1,3,2-
benzodioxaphosphorin-4-one crystal, which should either be a 
glassy green or white solid, before use). Then anh. DMF (0.17 mL) 
and tributylamine (0.23 mmol) were added to the 
tributylammonium pyrophosphate flask and sonicated to mix. The 
solution was added to the reaction mixture and stirred at room 
temperature for 45 minutes. In a separate vial, iodine (0.041g, 0.16 
mmol) was added to pyridine (0.98 mL) and H2O (20 µL) and 
sonicated to mix. The contents were then added to the reaction 
flask and stirred at room temperature for 30 minutes. The reaction 
was quenched with 10% Na2S2O3 (3 mL). The solvent was 
removed in vacuo while keeping the temperature of the water bath 
below 30°C. Then H2O (4 mL) was added and the reaction sat for 
30 minutes at room temperature. Solvent was removed under 
vacuum to afford crude triphosphate as a yellow oil. Products were 
purified via reverse phase HPLC (0-100% 0.1 M TEAB with 30% 
MeCN in 0.1 M TEAB, flow rate = 3.5 mL/min). Products were 
then purified further via ion-exchange chromatography utilizing 
Dowex 50WX2 Na+ charged resin. Column was washed with ultra-
pure H2O, 1M HCl, ultra-pure H2O, 1M NaOH, and finally ultra-
pure H2O before the sample was run through the column and 
washed with more ultra-pure H2O. All samples were then freeze 
dried by lyophilization for testing. 
Characterization of 2-((4-(2-amino-4-methoxypyrimidin-5-yl)-
1H-imidazol-1-yl)methoxy)ethyl tetrahydrogen triphosphate (1-
TP). 
Product is a white solid after lyophilization (0.029 g, 50.9%); 1H 
NMR (400 MHz, D2O) δ 8.3 (s, 1H), 7.9, (s, 1H), 7.5 (s, 1H), 5.4 
(s, 2H), 4.7 (s, 2H), 4.0 (m, 2H), 3.8 (s, 3H), 3.7 (m, 2H); 31P NMR 
(162 MHz, D2O) δ -9.5 (d, 1P), -10.5 (m, 1P), -22.6 (t, 1P); MS 
(ESI+) m/z calcd for C11H18N5O12P3 [M-H]: 504.02, found: 503.98. 
Characterization of 2-((4-(2,4-dimethoxypyrimidin-5-yl)-1H-
imidazol-1-yl)methoxy)ethyl tetrahydrogen triphosphate (2-TP). 
Product is a white solid after lyophilization (0.035 g, 62%); 1H 
NMR (400 MHz, D2O) δ 8.4, (s, 1H), 7.9 (s, 1H), 7.6 (s, 1H), 5.4 
(s, 2H), 4.0 (m, 2H), 3.9 (s, 3H), 3.8 (s, 3H), 3.6 (m, 2H); 13C NMR 
(126 MHz, D2O) δ 167.3, 163.4, 153.9, 138.4, 133.6, 119.4, 109.4, 
76.3, 68.2, 64.9, 55.0, 54.6; 31P NMR (162 MHz, D2O) δ -6.2 (d, 
1P), -10.4 (m, 1P), -22.1 (t, 1P); MS (ESI+) m/z calcd for 
C12H19N4O13P3 [M-H]: 519.22, found: 519.01. 
4.2. Enzyme Production and Purification 
The coding sequence corresponding to the ZIKV and DENV-3 
MTase domain were cloned in fusion with hist6-Tag in pQE30 
expression vector as previously described72, 73 and the 
corresponding protein were produced Escherichia coli T7 Express 
Iq (New England BioLabs). Cells were grown in Terrific Brother 
at 97°C until the optical density of 0.6 at 600 nm (OD600) and the 
Mtase expression was induced by adding 0.5 mM IPTG 
(isopropyl-β-d-thiogalactopyranoside) before overnight 
expression at 17°C. The bacteria were pellets and lysed in (50 mM 
Tris-HCl [pH 8], 300 mM NaCl, 5% glycerol, 0.1% Triton, 10 
µg/ml DNase I, 2 tablets of EDTA-free antiprotease cocktail 
[Roche], 0.25 mg/ml lysozyme). After sonication the clarified 
proteins were purified by immobilized metal affinity 
chromatography (IMAC, GE Healthcare), and after, several 
washes of elution were performed in 50 mM Tris-HCl, 300 mM 
NaCl, and 250 mM imidazole (pH 8.0). The eluted proteins were 
then separated by gel filtration on a 16/60 Superdex 200 (GE 
Healthcare) equilibrated in a mixture of 10 mM HEPES, 500 mM 
NaCl, 5% glycerol, and 1mM dithiothreitol (DTT [pH 7.5]). 
For the NS5 polymerase encoding both MTase and RdRp 
activities, the gene coding for a N-terminal His6-tagged DENV 
NS5 (serotype 2, strain New Guinea C) was cloned in a pQE30 
expression plasmid as described previously in Selisko et. al.74 
Expression and purification was as described by Potisopon et. al.75 
The synthetic ZIKV NS5 gene cloned in a pQE30 expression 
plasmid was obtained from Genescript. The sequence used was 
from strain H/PF/2013 from French Polynesia, Genbank acc# 
KJ776791. The ZIKV NS5, carrying His6-tag at its N-terminus, 
was produced as described above for DENV NS5 with the 
exception that IMAC TALON beads were washed with 1.5 M 
NaCl. SEC was performed using a Superdex S75 HR 16/20 
column (GE Healthcare) with SEC buffer 50mM HEPES pH 7.5, 
750 mM NaCl, 10% glycerol, 10 mM DTT. After the second 
purification step, proteins were concentrated up to around 8 mg/ml 
(78 µM NS5) and stored at -20°C after adding glycerol to a final 
concentration of 40%. Protein purity was higher than 95% as 
judged by SDS-PAGE. Protein stock concentrations were 
determined by absorbance measurements at 280 nm using a 
Nanodrop 2000 (Thermo Scientific). 
4.3. DENV and ZIKV 2’-O-MTase Assay 
DENV-3 and ZIKV 2’-O-MTase activity was followed by 
incubating the MTase (0.5 µM) with small capped RNA substrate 
GpppAC5 in the presence of [3H]AdoMet.76 The MTase activity 
assay was performed in 20 µL samples containing 40 mM Tris-
HCl pH 7.5, 5 mM DTT, 10 µM AdoMet (0.2-2 µCi [3H]AdoMet), 
0.5 µM of MTase, 1 µM GpppAC5, and the inhibitors. The reaction 
was incubated at 30°C for 30 minutes and stopped by 20-fold 
filution in an ice-cold 100 µM AdoHcy solution. Samples were 
then transferred onto a DEAE membrane (DEAE Filtermat; 
Wallac) by a Filtermat Harvester (Packard Instruments) washed 
with 0.01 M ammonium formate (pH 8.0), water, and ethanol, and 
the radioactivity transferred onto RNA was measured using a 
Wallac 1450 MicroBeta Trilux Liquid Scintillation Counter.72 
The inhibitor concentration at 50% activity (IC50) was 
determined by performing DENV-3 and ZIKV MTase assays, in 
the presence of a serial dilution of the inhibitor. All data points 
were measure in triplicate. The IC50 values were determined using 
Prism software and adjusted to a logistic dose-response function: 
% activity = 100/(1+[I]/IC50)b, where b corresponds to the slope 
factor and [I] to inhibitor concentration.77 
4.4. Molecular Modeling 
All molecular modeling studies were performed on a Viglen 
Genie Intel®Core™ i7-3770 vPro CPU@ 3.40 GHz x 8 running 
Ubuntu 14.04. The MTase structures were downloaded from the 
PDB data bank (http://www.rcsb.org/; PDB codes 5GOZ,79 
4V0R,80 3EVD,81 and 5E9W82). GTP coordinates for the human 
N7 MTase crystal structure 5E9W were obtained from the E. 
cuniculi cap-MTase Ecm1 crystal structure 1RI1, which is in 
complex with GTP.70 This was done after structural 
superimposition of 5E9W with 1RI1, which reveals a highly 
conserved architecture and amino acid residue composition for the 
GTP binding pockets of the two proteins. Hydrogen atoms were 
added to the proteins, using the Protonate 3D routine of the 
Molecular Operating Environment (MOE).82 Ligand structures 
were built with MOE and minimized using the MMFF94x force 
field until a RMSD gradient of 0.05 kcal mol-1 Å-1 was reached. 
The docking simulations were performed using PLANTS applying 
the following parameters: search algorithm: aco_ants 20, aco_evap 
0.15, aco_sigma 2.0; binding site: 5GOZ: bindingsite_center 
[5.952 45.608 -22.492], bindingsite_radius 9; 4V0R: 
bindingsite_center [-28.826 -19.856 -30.783], bindingsite_radius 
9;  3EVD: bindingsite center [27.897 24.789 -44.440], bindingsite 
radius 9; 5E9W: bindingsite center [15.299 37.929 95.164], 
binding radius 9; cluster algorithm: cluster_rmsd 2.0, 
cluster_structures 30; scoring function: chemplp.83 Docking 
results were visually inspected using MOE. 
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